GlassScriptPhysician profile
Myles B Benjamin
NPI 1831474485
$4,331.27
in general payments reported to CMS, 2019-2025
34 companies · $518 in 2025
The $518 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,436 · 2022: $723 · 2023: $798 · 2024: $856 · 2025: $518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,172.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $733.61 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $581.47 | 2021-2025 | |
| Novo Nordisk INC | $574.34 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Amarin Pharma, INC. | $422.08 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $389.58 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Abbott Laboratories | $223.35 | 2021-2023 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $142.73 | 2021-2024 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.65 | 2021-2024 | Jardiance |
| Glaxosmithkline, LLC. | $105.79 | 2021-2024 | Trelegy Ellipta |
| Biotronik INC. | $100.53 | 2021 | |
| Axsome Therapeutics, INC. | $91.42 | 2024-2025 | Auvelity |
| Pfizer INC. | $74.15 | 2021-2024 | |
| Exact Sciences Corporation | $67.67 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Clarus Therapeutics INC. | $65.23 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $56.13 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $54.63 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.91 | 2021-2023 | Xifaxan |
| Amgen INC. | $49.94 | 2024-2025 | Repatha, Otezla, Repatha |
| Kowa Pharmaceuticals America, INC. | $49.86 | 2021-2022 | |
| Mylan Specialty L.P. | $47.37 | 2022-2023 | Yupelri |
| Abiomed | $40.89 | 2025 | |
| Astellas Pharma US INC | $37.70 | 2023 | Veozah |
| Antares Pharma, INC. | $36.16 | 2023-2024 | Xyosted, Nocdurna, Tlando |
| Esperion Therapeutics, INC. | $27.67 | 2021-2024 | Nexletol |
| Phathom Pharmaceuticals, INC. | $26.81 | 2024-2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $26.62 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $22.64 | 2022 | |
| Recor Medical INC | $17.55 | 2025 | Paradise Ultrasound Renal Denervation System |
| Arbor Pharmaceuticals, INC. | $16.97 | 2022 | |
| Seqirus USA INC | $16.96 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Ironwood Pharmaceuticals, INC | $15.08 | 2021 | |
| Xeris Pharmaceuticals, INC. | $14.18 | 2024 | Gvoke Hypopen |
| Idorsia Pharmaceuticals US INC | $12.88 | 2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $12.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Myles Benjamin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.